Home » Stocks » Millendo Therapeutics

Millendo Therapeutics, Inc. (MLND)

Stock Price: $1.83 USD 0.02 (1.10%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 34.77M
Revenue (ttm) n/a
Net Income (ttm) -47.00M
Shares Out 19.00M
EPS (ttm) -2.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 22, 2020
Last Price $1.83
Previous Close $1.81
Change ($) 0.02
Change (%) 1.10%
Day's Open 1.81
Day's Range 1.78 - 1.88
Day's Volume 201,830
52-Week Range 1.26 - 9.88

More Stats

Market Cap 34.77M
Enterprise Value n/a
Earnings Date (est) Nov 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 19.00M
Float 15.43M
EPS (basic) -2.95
EPS (diluted) -2.87
FCF / Share -2.01
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 686,349
Short Ratio 2.56
Short % of Float 4.45%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 0.78
Revenue n/a
Operating Income -47.51M
Net Income -47.00M
Free Cash Flow -38.22M
Net Cash 47.54M
Net Cash / Share 2.50
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -47.15%
ROE -94.03%
ROIC -1,902.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 2
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(136.61% upside)
Current: $1.83
Target: 4.33
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth---135.74%----
Gross Profit----4.75-1.97---
Operating Income-45.61-27.04-84.33-81.01-72.00-47.93-29.13-13.53
Net Income-44.57-27.19-84.58-82.26-73.22-49.52-29.04-13.51
Shares Outstanding13.711.550.262.141.811.511.080.39
Earnings Per Share-3.25-17.58-321.81-38.40-40.50-32.85-27.00-34.95
Operating Cash Flow-41.22-23.65-20.34-61.73-50.29-30.59-18.09-11.16
Capital Expenditures-0.40-0.04--2.59-5.23-2.80-0.72-0.85
Free Cash Flow-41.62-23.68-20.34-64.32-55.52-33.39-18.81-12.01
Cash & Equivalents63.5177.7217.6211512760.4344.5231.48
Total Debt4.520.570.77-----
Net Cash / Debt58.9977.1416.8511512760.4344.5231.48
Book Value58.5570.95-13110812755.3341.7030.72
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Millendo Therapeutics, Inc.
Country United States
Employees 37
CEO Julia C. Owens

Stock Information

Ticker Symbol MLND
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MLND


Millendo Therapeutics, a late-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; and nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia. Millendo Therapeutics, Inc. is headquartered in Ann Arbor, Michigan.